Search
Advertisement
prashun talukdar
Prashun Talukdar

Prashun Talukdar

tvtn

prashun.talukdar@aajtak.com

With a long experience in the digital space, Prashun has seen it all (mostly at least). From dot-com bubbles to crypto crazes. When it comes to covering the stock markets, he is constantly on the trail to look out for the next big trend. But don't let the seriousness of the stock market fool you. Outside of work, you can often find him strolling Insta, scrolling through memes or binge-watching cartoons.

And when Prashun is not glued to his phone, he's checking out the latest automobile launches – because le...

SHOW MORE...

Broader markets outperformed the headline indices

Sensex, Nifty outlook for tomorrow: What lies ahead for the stock market?

by Prashun Talukdar |May 13, 2026

The 30-share BSE Sensex pack gained 49.74 points or 0.07 per cent to close at 74,608.98, while the NSE Nifty50 index rose 33.05 points or 0.14 per cent to settle at 23,412.60.

Despite the earnings growth, Paras Defence shares extended losses for the fourth consecutive session on Wednesday.

Paras Defence Q4 profit jumps 74%; stock extends decline, still up 13% in a month: Target prices, outlook

by Prashun Talukdar |May 13, 2026

Paras Defence: Profit attributable to owners of the company came in at Rs 34.38 crore during the quarter under review, compared with Rs 19.72 crore in the corresponding period last year.

Sharing his stock-specific views on Tata Power and Adani Power, the market expert outlined key levels investors should watch.

Tata Power, Adani Power shares: Buy now or wait? | Daily Calls on BTTV

by Prashun Talukdar |May 13, 2026

Tata Power shares slipped 3.36 per cent to close at Rs 404.35, while Adani Power moved up 2.05 per cent to Rs 213.90 level.

MOFSL maintained its 'Neutral' rating on Dr Reddy's while cutting the target price to Rs 1,195.

Dr Reddy's Laboratories shares: Poor Q4 show — Buy, sell or hold?

by Prashun Talukdar |May 13, 2026

Brokerages largely flagged pressure on earnings and margins during the quarter, though some continued to remain constructive on the drugmaker's long-term growth prospects, driven by semaglutide and bi...

"We remain positive on the sector from a medium to long-term perspective — in the near term, expect volatility to persist," Nuvama noted.

IT stocks: Rebound soon? How Gen AI is driving sentiment — 'Buy' calls, target prices

by Prashun Talukdar |May 13, 2026

The brokerage said Indian IT services companies delivered largely in-line quarterly results, with revenue growth and margins staying stable.

HPCL: Capital expenditure (capex) during the quarter came at Rs 4,611 crore, while cumulative capex for FY26 stood at Rs 15,705 crore.

HPCL shares rise as Q4 profit jumps 78%; dividend, record date announced

by Prashun Talukdar |May 13, 2026

HPCL: Revenue from operations rose 4.45 per cent YoY to Rs 1,23,602 crore in Q4 FY26, compared with Rs 1,18,334 crore in the year-ago period.

Vijay Kedia's office acquired a stake in the company through a bulk deal.

Shares up 26% in five sessions: Ace investor Vijay Kedia picks this debt-free IT stock

by Prashun Talukdar |May 13, 2026

Amid heightened price action, both BSE and NSE have placed the stock under the short-term Additional Surveillance Measure (ASM) framework.

On market targets, Morgan Stanley said its base case for the benchmark index implies steady upside through 2027.

Morgan Stanley sees Sensex at 89,000 by June 2027; projects 15% upside on earnings revival, macro tailwinds

by Prashun Talukdar |May 13, 2026

In its latest commentary released on May 12, the global brokerage said earnings are moving past a mid-cycle slowdown and are expected to accelerate further.

The brokerage noted that adjusted profit after tax (PAT) rose 3.2 times YoY to Rs 44.3 crore, broadly in line with estimates. (Pic source: AI generated image for representational purposes)

MTAR Technologies shares slip despite 3x Q4 profit jump, still up 138% in 6 months — What's weighing on sentiment?

by Prashun Talukdar |May 13, 2026

The stock was last seen trading 1.78 per cent lower at Rs 6,139.05. Despite the day's fall, the counter has seen a sharp rally in recent months, gaining 39.52 per cent in the past one month and delive...

Dr Reddy's Q4: EBITDA for the quarter came in at Rs 980 crore, marking a 60 per cent YoY decline.

Dr Reddy's Q4: Why profit fell 86% YoY to Rs 221 crore; Rs 8 dividend, record date announced

by Prashun Talukdar |May 12, 2026

Dr Reddy's Q4: The company's revenue from operations in Q4 FY26 declined 12 per cent YoY to Rs 7,516 crore versus Rs 8,506 crore in the corresponding quarter of the previous financial year.